Clinical trialNCT00761098UnknownPhase 4Interventional

Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)

SponsorWeill Medical College of Cornell UniversityEnrollment80CirrhosisSpontaneous Bacterial Peritonitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Spontaneous bacterial peritonitis (SBP) is a common and frequently fatal complication of end-stage liver disease with a mortality of up to 10%, primarily due to the development of kidney failure. Current standard practice is to treat this infection with broad spectrum antibiotics and salt-poor albumin administration on day one and three of treatment. In this study the investigators test the hypothesis that the administration of a second dose of albumin at 48 hours only to patients with renal insufficiency, is as effective at preventing kidney failure as administering the second dose to all patients at 72 hours.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ilan S Weisberg, MD
New York Presbyterian Hospital - Cornell/Columbia
Study Director
clinicaltrials.gov ↗
Samuel H Sigal, MD
New York Presbyterian Hospital - Cornell/Columbia
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

New York Presbyterian Hospital - Columbia University Medical Center
New York, New York, United States
Brian Kim, MDIlan S Weisberg, MDLorna Dove, MD, MPHReem Sharaiha, MDRobert Brown, MD, MPHSamuel H Sigal, MDScott Fink, MD
Recruiting
New York Presbyterian Hospital - Weill Cornell Medical Center
New York, New York, United States
Arun Jesudian, MDIlan S Weisberg, MDSamuel H Sigal, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ExperimentalStandard Care

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2005
Primary completion: 31 May 2010
Completion: 31 Aug 2010
Last update posted: 4 Jan 2011
Registered enrollment: 80
Registry id: NCT00761098

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.